In addition to its important role in preventing cancer in patients and their close family members, identification of pathogenic or likely pathogenic variants, at least in BRAC1 and BRCA2, may inform therapeutic decisions in common cancers including breast, ovarian, prostate, and pancreatic cancers. Here, BRCA2 is linked to familial pancreatic carcinoma.